Creative India: tapping the full potential
India’s creative economy is large, but its untapped potential is even larger. This study provides the first reliable measure on the size of India’s creative economy, explores the many challenges faced
Intellectual Property Rights (IPR)
-
World patent report 2008: a statistical review
Intellectual property rights have been high on the policy agenda in recent years.
-
China Plans $3.5 Billion GM Crops Initiative
Confronted with land degradation, chronic water shortages, and a growing population that already numbers 1.3 billion, China is looking to a transgenic green revolution to secure its food supply. Later this month, the government is expected to roll out a $3.5 billion research and development (R&D) initiative on genetically modified (GM) plants. "The new initiative will spur commercialization of GM varieties," says Xue Dayuan, chief scientist on biodiversity at the Nanjing Institute of Environmental Science of the Ministry of Environmental Protection.
-
Toward a new era of intellectual property: from confrontation to negotiation
Intellectual property occupies a central position in the biotechnology innovation system, the expected source of new medicines, foods and bio-energy.
-
Climate change, technology transfer and intellectual property rights
Technological solutions are imperative in meeting the challenges of climate change. A critical factor in greenhouse gas emissions, technology is also fundamental to enhancing existing abilities and lowering the costs of reducing these emissions.
-
Ranbaxy sell-out: Reversal of fortunes
The Ranbaxy sale to Daiichi Sankyo could herald a new phase in the evolution of the Indain pharmaceutical industry. In order to cope in a world after the agreement on Trade-related Aspects of Intellectual Property Rights came into force, some of the larger Indian firms pursued the two strategies of a greater internationalisation of sales of generic drugs and a focus on research and development as junior partners of global giants. Ranbaxy had mixed success with the two strategies.
-
Elements of an international regime for the recognition of national regulations on access to genetic resources
This paper aims to assist the international community in its efforts to curb the misappropriation of genetic resources and associated traditional knowledge through IPRs. It outlines how an international legal regime may assist the enforcement of decisions made under national access and benefit-sharing regulations by providing for the recognition of such decisions in foreign jurisdictions.
-
Completing the circle
Subject to the approval of the shareholders and the usual regulatory and statutory rubber stamps, India's largest pharmaceutical company, Ranbaxy Laboratories, is expected, by the end of March 2009 to become a subsidiary of Daiichi Sankyo, one of the leading pharmaceutical companies of Japan.
-
Intellectual property rights policy for Kerala 2008
The Intellectual Property Rights (IPRs) Policy for Kerala puts forth the concept of 'knowledge commons' and 'commons licence' for traditional knowledge. The policy says that all traditional knowledge, including traditional medicine, must belong to the domain of "knowledge commons" and not to public domain. The system should be introduced through legal arrangements. While community or family custodians will have rights to knowledge that belonged to them, the rest of the traditional knowledge will belong to Kerala State.
-
Trade and climate change: issues in perspective
This volume is the result of a trade and climate change seminar held in Copenhagen in June 2008. Following the structure of that seminar, it explores six themes that link trade and investment to climate change, for each asking where trade policy might be of service to climate change objectives.
-
GVK Bio, Wyeth sign drug discovery pact
GVK Bio has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to undertake drug discovery research and generate intellectual property (IP). Based on the research output, the company would file INDs (Investigative New Drug) with the US Food & Drug Administration. The work would be largely on drug candidates focused on pre-defined discovery targets. GVK Bio, the Hyderabad-based company, will utilise in-house capabilities in discovery chemistry, informatics, biology and toxicology to advance this collaborative programme expected to be between 2-3 years.